Drug Profile
CNV 2197944
Alternative Names: CNV-2197944Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Calchan
- Class Analgesics; Small molecules
- Mechanism of Action N type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic neuropathies; Postherpetic neuralgia
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in United Kingdom (PO)
- 30 Jun 2014 Convergence Pharmaceuticals completes a phase II trial in Diabetic neuropathies in Hungary, Czech Republic, Bulgaria & Poland (NCT01893125) (EudraCT2013-000407-16)
- 06 Feb 2014 Convergence Pharmaceuticals completes a phase II trial in Postherpetic neuralgia in Bulgaria and South Africa (NCT reference)